Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis | 6 | 2023 | 50 | 1.800 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2018 | 144 | 1.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2018 | 500 | 1.040 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2026 | 140 | 0.860 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2026 | 142 | 0.630 |
Why?
|
| Fibroblasts | 5 | 2026 | 849 | 0.600 |
Why?
|
| Granuloma | 2 | 2016 | 59 | 0.560 |
Why?
|
| Interleukin-17 | 1 | 2018 | 125 | 0.530 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 25 | 0.500 |
Why?
|
| Up-Regulation | 2 | 2018 | 825 | 0.490 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 229 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2022 | 480 | 0.480 |
Why?
|
| Anti-Infective Agents | 2 | 2016 | 266 | 0.480 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2021 | 429 | 0.450 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 71 | 0.430 |
Why?
|
| Killer Cells, Natural | 2 | 2014 | 355 | 0.420 |
Why?
|
| Organotin Compounds | 1 | 2013 | 6 | 0.400 |
Why?
|
| Trialkyltin Compounds | 1 | 2013 | 8 | 0.400 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 183 | 0.370 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 176 | 0.370 |
Why?
|
| Lung | 5 | 2026 | 1535 | 0.360 |
Why?
|
| Bleomycin | 5 | 2026 | 116 | 0.330 |
Why?
|
| Gene Expression Regulation | 6 | 2022 | 2323 | 0.310 |
Why?
|
| Signal Transduction | 4 | 2021 | 4686 | 0.280 |
Why?
|
| Sarcoidosis, Pulmonary | 2 | 2017 | 9 | 0.240 |
Why?
|
| Pinocytosis | 1 | 2026 | 11 | 0.240 |
Why?
|
| Amiloride | 1 | 2026 | 29 | 0.240 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2024 | 125 | 0.230 |
Why?
|
| Cell Proliferation | 5 | 2024 | 2465 | 0.230 |
Why?
|
| Syndecan-2 | 2 | 2022 | 10 | 0.220 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2024 | 19 | 0.220 |
Why?
|
| Autophagy | 2 | 2024 | 417 | 0.200 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 105 | 0.200 |
Why?
|
| Fibrosis | 1 | 2024 | 429 | 0.190 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 408 | 0.170 |
Why?
|
| Pulmonary Fibrosis | 1 | 2022 | 112 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 463 | 0.160 |
Why?
|
| Lung Injury | 1 | 2022 | 126 | 0.160 |
Why?
|
| Apoptosis | 2 | 2024 | 1827 | 0.160 |
Why?
|
| Mice | 8 | 2026 | 18301 | 0.150 |
Why?
|
| Demography | 2 | 2017 | 237 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 284 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2018 | 110 | 0.140 |
Why?
|
| Th17 Cells | 1 | 2018 | 101 | 0.130 |
Why?
|
| Th1 Cells | 1 | 2017 | 158 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2026 | 4697 | 0.110 |
Why?
|
| Humans | 16 | 2026 | 131163 | 0.110 |
Why?
|
| Animals | 8 | 2026 | 33912 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 1419 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2017 | 3359 | 0.110 |
Why?
|
| Polybrominated Biphenyls | 1 | 2014 | 5 | 0.110 |
Why?
|
| Flame Retardants | 1 | 2014 | 4 | 0.110 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2014 | 5 | 0.110 |
Why?
|
| Antimalarials | 1 | 2015 | 40 | 0.110 |
Why?
|
| Lymphocyte Depletion | 1 | 2015 | 124 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2013 | 14 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 386 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 136 | 0.100 |
Why?
|
| Aged | 5 | 2018 | 21025 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 88 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2014 | 1571 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1618 | 0.100 |
Why?
|
| Ubiquitination | 2 | 2023 | 173 | 0.090 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2550 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 333 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 639 | 0.090 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 2 | 2022 | 7 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 509 | 0.090 |
Why?
|
| Male | 9 | 2026 | 64957 | 0.090 |
Why?
|
| Middle Aged | 5 | 2018 | 28601 | 0.090 |
Why?
|
| Adult | 5 | 2018 | 31282 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 335 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2024 | 576 | 0.070 |
Why?
|
| Primary Cell Culture | 2 | 2021 | 106 | 0.070 |
Why?
|
| Young Adult | 3 | 2017 | 10103 | 0.070 |
Why?
|
| Female | 6 | 2018 | 70963 | 0.060 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2026 | 179 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2023 | 3819 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2023 | 36 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2023 | 43 | 0.050 |
Why?
|
| Scleroderma, Systemic | 1 | 2024 | 118 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 255 | 0.050 |
Why?
|
| Androgens | 1 | 2024 | 247 | 0.050 |
Why?
|
| Citrullination | 1 | 2022 | 4 | 0.050 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2022 | 6 | 0.050 |
Why?
|
| Sp1 Transcription Factor | 1 | 2022 | 39 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 1011 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2023 | 359 | 0.040 |
Why?
|
| Lysosomes | 1 | 2023 | 268 | 0.040 |
Why?
|
| Skin | 1 | 2024 | 545 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2023 | 544 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2024 | 446 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2021 | 123 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 808 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2021 | 440 | 0.040 |
Why?
|
| Clonal Anergy | 1 | 2017 | 2 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2017 | 59 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2021 | 687 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3748 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1928 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2022 | 2326 | 0.030 |
Why?
|
| Mycobacterium | 1 | 2016 | 30 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2016 | 437 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 633 | 0.030 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2014 | 13 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2014 | 33 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2014 | 45 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2014 | 62 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 481 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2014 | 88 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2014 | 56 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 107 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 526 | 0.030 |
Why?
|
| Antibodies | 1 | 2014 | 322 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 765 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2885 | 0.020 |
Why?
|
| Cytokines | 1 | 2017 | 1339 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4497 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2200 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1591 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 3385 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 1545 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 20987 | 0.010 |
Why?
|